Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

BACKGROUND: The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. METHODS: Relapsed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Hong, Jung Yong, Lee, Ho Sup, Oh, Sung Yong, Shin, Ho-Jin, Kong, Jee Hyun, Yi, Jun Ho, Sakamoto, Kana, Ko, Young Hyeh, Huh, Jooryung, Lee, Seung-Sook, Takeuchi, Kengo, Shin, Dong-Yeop, Suh, Cheolwon, Kim, Won Seog
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842512/
https://ncbi.nlm.nih.gov/pubmed/31707975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6303-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados